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Abstract
Background: Endemic Kaposi sarcoma (KS) was first described in African children over fifty years ago, but has
recently been overshadowed by HIV-related disease. We aimed to evaluate the similarities and differences between
endemic HIV-negative and epidemic HIV-positive pediatric KS in a KS-associated herpesvirus-endemic region of
Africa.
Methods: We describe clinical characteristics of 20 HIV-negative children with endemic KS over a six-year period
and compare findings with a historical control—an HIV-related pediatric KS cohort from Lilongwe, Malawi.
Results: The HIV-negative endemic KS cohort was 70% male with a median age of 9.3 years. Lymph node
involvement was present in 50%, hyperpigmented skin lesions in 45%, and woody edema in 40%. One patient
(5%) presented with oral KS involvement and no patients presented initially with visceral KS. Significant anemia
(hemoglobin < 8 g/dL) and thrombocytopenia (platelet count < 100 × 109/L) were found at time of original KS
diagnosis in 45 and 40% respectively. In both HIV-negative and HIV-positive cohorts, lymphadenopathy was
the most common presentation, prototypical skin lesions were often absent, severe cytopenias were a
common clinical feature, and treatment outcomes were similar. Patients with endemic KS demonstrated less
frequent oral involvement (5% versus 29%, P = 0.03) and a lower proportion of patients with visceral
involvement (0% versus 16%, P = 0.06).
Conclusions: These data suggest clinical overlap between epidemiological variants. Treatment protocols for
pediatric KS in sub-Saharan Africa should be devised to include both endemic HIV-negative and epidemic
HIV-related disease to better define the clinical and biological comparison.
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Introduction
Descriptions of endemic Kaposi sarcoma (KS) of childhood
originated more than fifty years ago in central and eastern
Africa—decades before the emergence of HIV—offering
details of the clinical characteristics and outcomes in
HIV-negative African children living in regions with en-
demic human herpesvirus-8/KS-associated herpesvirus
(KSHV) infection [1–5]. Unique features of endemic
pediatric KS that were distinct from adults included
frequent presentation primarily with lymph node dis-
ease, less frequent skin involvement, and a fulminant
clinical course if untreated—especially for children with
lymphadenopathic KS [3, 4].
Following those initial descriptions, little has been pub-
lished on endemic HIV-unrelated KS [6–9]. With the
alarming rise in HIV infection rates across sub-Saharan
Africa over the past 25 years, the spotlight has shifted to-
wards HIV-related KS. Increased efforts to treat pediatric
HIV infection and its complications in sub-Saharan Africa
have resulted in greater awareness and understanding of
HIV-related KS in children [6, 7, 10–17]. Clinical patterns
of HIV-related pediatric KS appear to overlap with the
early observations of endemic KS from fifty years ago. The
same unique features of predilection for lymph node in-
volvement and its characteristic association with fulmin-
ant disease progression have distinguished it from KS in
HIV-infected adults [11, 12, 14–16, 18].
In this brief report, we describe the clinical features
and treatment outcomes of endemic pediatric KS and
compare it to our previously published experience with
HIV-related pediatric KS in Lilongwe, Malawi.
Methods
Medical records of HIV-negative children and adoles-
cents (< 18 years) with a histological or clinical diagnosis
of endemic KS between January 2011 and December
2016 were reviewed. HIV status was determined based
upon standard clinical procedure using rapid antibody
testing and all patients underwent repeat testing for con-
firmation to rule-out the potential for a false-negative
result. The initial ten patients also underwent qualitative
HIV DNA PCR testing for additional confirmation of their
HIV-negative status. Diagnostic and therapeutic algorithms
have been previously described, including supportive care
strategies [16]. In brief, first line chemotherapy was a com-
bination of bleomycin and vincristine (BV); patients with
relapsed/refractory disease received doxorubicin plus BV,
and the third-line chemotherapy option was paclitaxel.
Patients were staged according to the Lilongwe Pediatric
KS Staging Classification, a pediatric-specific staging para-
digm that attempts to address the unique clinical features
of childhood KS observed in KSHV-endemic regions of
Africa [17, 19]. Briefly, this staging classification differenti-
ates four distinct clinical phenotypes with contrasting
disease characteristics and treatment outcomes. Stage 1
includes patients with mild (stage 1A) to moderate (stage
1B) disease limited to the skin, subcutaneous tissue, oral
mucosa, and conjunctiva. Stage 2 is defined as lympha-
denopathic KS, while stage 3 is characterized by the
presence of woody edema. Stage 4 is the group with the
worst long-term survival and includes patients with vis-
ceral disease and those with 20 or more hyperpigmented
skin/oral lesions in widespread distribution [17, 19].
Data from endemic KS patients were compared to data
from a previously described cohort of HIV-related pediatric
KS at the same institution [16]. All statistical analyses were
performed using STATA v.13.1, and P-values were gen-
erated using either a k-sample equality-of-medians test,
Chi-square test, or Fisher’s exact test, as appropriate.
The study was approved by the Malawi National Health
Sciences Research Committee and the Baylor College of
Medicine Institutional Review Board for Human Subjects;
a waiver of consent was obtained due to the retrospective
nature of the study.
Results
Clinical characteristics of endemic pediatric KS
There were 20 children (70% male) diagnosed with en-
demic KS between 2011 and 2016. In comparison, there
were 140 new HIV-related pediatric KS diagnoses over the
same six-year time period [20]. Additional file 1: Figure S1
demonstrates a comparison of the histopathological
appearance of lymphadenopathic KS in both endemic
and HIV-related KS. The most common clinical site of
endemic KS involvement was lymph node (50%) followed
by hyperpigmented skin lesions (45%) and woody edema
(40%, Table 1). No patient had visceral involvement on
original presentation and one (5%) presented with
oral involvement. Nine (45%) patients presented with
moderate-severe anemia (hemoglobin < 8 g/dL) and 8
(40%) with moderate-severe thrombocytopenia (platelet
count < 100 × 109/L).
At a median follow-up of 39 months (interquartile
range 27–62), 13 patients (65%) were alive. Nine (45%)
were in complete remission (CR, defined as complete
and sustained disappearance of all KS lesions), 3 (15%)
were alive with stable disease, and 1 patient had experi-
enced relapse and was receiving salvage chemotherapy.
Seven (35%) patients died at median time of 2 months
(range 0.1–52) from the date of KS diagnosis. Six of
those deaths were attributed to KS and there were no
treatment-related deaths.
Comparison of endemic and HIV-related pediatric KS
Comparing this series of 20 children with endemic KS
to our previously published cohort of 70 children with
HIV-related KS, some similarities and differences
emerged (Table 1).
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In both cohorts, KS lymphadenopathy was the most
common presenting feature, although this occurred
more frequently among HIV-related KS cases (P = 0.03).
Approximately one-fourth of both cohorts presented with
KS lymphadenopathy in the absence of prototypical
skin/oral lesions or woody edema (P = 0.95). Hyperpig-
mented skin lesions were present in around half of
both cohorts (P = 0.21). Moderate-severe anemia and/
or thrombocytopenia commonly occurred in both epi-
demiological variants (P = 0.54 and P = 0.32, respectively).
Distinctions between endemic and HIV-related KS
were demonstrated as well. Patients with endemic KS
had a lower frequency of oral KS involvement
(P = 0.03) compared to the HIV-related control group.
None of the endemic KS patients originally presented
with visceral disease compared to 16% of HIV-related
KS patients (P = 0.06), and the endemic KS cohort was
70% male compared to 50% in the HIV-related KS co-
hort (P = 0.11). Ultimately, treatment outcomes were
similar (P = 0.31).
Treatment outcomes
Nineteen patients were initiated on the chemotherapy
regimen described above, with one patient having died
prior to initiation of chemotherapy. Sixteen patients com-
pleted the treatment protocol and 3 died from refractory
KS that progressed despite chemotherapy. Survival in con-
text of the Lilongwe Pediatric KS Staging Classification
was explored (Table 2) [17, 19]. In summary, 8 of 10 pa-
tients (80%) with stage I/II KS were alive in CR with
follow-up ranging 14–62 months from time of KS diagno-
sis. Among the 10 patients with stage III/IV KS, only
one (10%) was alive in CR. Five (50%) patients with
stage III/IV disease died from relapsed/refractory KS,
while 4 (40%) were alive with stable disease.
Mortality patterns were categorized in context of the
pediatric-specific staging paradigm as well (Table 2). No
patient fit criteria for stage 1A (mild cutaneous/oral KS).
Of the 4 patients categorized as stage 1B (moderate cu-
taneous/oral KS), there was one death, occurring in a
patient who presented concurrently with KS (diagnosed
Table 1 Clinical Characteristics of Children with Endemic HIV-Negative KS vs HIV-Related KS
Epidemiologic subtype of kaposi sarcoma Endemic HIV-related p
Number of Patients 20 70
Number of Females 6 (30%) 35 (50%) 0.11a
Median Age in years (range) 9.3 (2.0–16.3) 8.4 (1.7–17.9) 0.57b
Pathology Confirmation 8 (40%) 14 (20%) 0.07a
Clinical Site(s) of KS Involvement
Lymph Node 10 (50%) 52 (74%) 0.03a
Hyperpigmented Skin Lesions 9 (45%) 42 (60%) 0.21a
Woody Edema 8 (40%) 17 (24%) 0.18a
Flesh Colored Subcutaneous Nodules 7 (35%) 23 (33%) 0.89a
Oral 1 (5%) 20 (29%) 0.03c
Lymph Node ONLY 5 (25%) 18 (26%) 0.95a
Visceral 0 11 (16%) 0.06c
Disseminated (ie ≥20) Hyperpigmented Skin/Oral Lesions 4 (20%) 7 (10%) 0.26c
Anemia (hemoglobin < 8) at KS diagnosis 9 (45%) 25 (37%) * 0.54a
Thrombocytopenia (platelet count < 100) at KS diagnosis 8 (40%) 19 (28%) * 0.32a
Treatment Outcome
Alive in Complete Remission 9 (45%) 33 (47%) 0.31c
Alive with Stable Disease 4 (20%) 6 (9%)
Death 7 (35%) 31 (44%)
Lilongwe Pediatric KS Staging Classification*
Stage 1A (mild cutaneous/oral KS) 0 0 0.08c
Stage 1B (moderate cutaneous/oral KS) 4 (20%) 3 (4%)
Stage 2 (lymphadenopathic KS) 6 (30%) 34 (50%)
Stage 3 (woody edema KS) 6 (30%) 14 (21%)
Stage 4 (visceral and/or disseminated KS) 4 (20%) 17 (25%)
Legend: KS Kaposi sarcoma, * in the HIV-related KS cohort, 67 patients had baseline blood count assessments and 68 patients were fully staged.aP-value estimated
using the Chi-square test;bChi-square P-value estimated from the k-sample equality of medians test;cP-value estimated using the Fisher’s exact test
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clinically with prototypical skin and conjunctival eye le-
sions) and histologically-confirmed Hodgkin lymphoma.
This patient died of refractory and progressive lymph-
oma; the KS lesions had completely resolved. Among the
6 patients in stage 2 (lymphadenopathic KS), there was
also one death, occurring secondary to severe cytopenias
on the first day of hospitalization, before chemotherapy
could be initiated.
Of the 6 patients categorized as stage 3 (woody edema
KS), 1 was in CR, 3 were alive with stable disease off
chemotherapy, and 2 had died. One death occurred in a
child that was lost to follow-up after six months of
chemotherapy and was subsequently found to have died
one year later, via telephone communication. The other
death occurred in a child that originally presented with
woody edema, hyperpigmented skin lesions, and lymph-
adenopathy, eventually evolving with the second relapse
to include pulmonary visceral involvement with severe
serosanguineous pleural effusions. All 4 of the patients
categorized as stage 4 originally presented with dissemi-
nated cutaneous/oral KS (widespread distribution of ≥20
hyperpigmented skin/oral lesions) and without visceral in-
volvement. Three of them were refractory to chemother-
apy and their underlying KS rapidly progressed (time of
death ranged 0.5–2 months). One patient achieved CR
with up-front intensified chemotherapy (doxorubicin plus
BV), however eventually experienced relapse 34 months
after the original diagnosis and was alive with stable dis-
ease but receiving salvage chemotherapy with paclitaxel at
the time of data analysis.
Discussion
This cohort of HIV-negative children and adolescents with
endemic KS shows considerable overlap with HIV-related
disease. Primary presentation with lymphadenopathy was a
consistent clinical feature in both pediatric endemic and
HIV-related KS cohorts. Additionally, in both epidemio-
logical variants, presentation with severe cytopenias is fre-
quent and approximately half of the patients lacked the
prototypical hyperpigmented skin/oral lesions that are so
often relied upon as a clinical indicator of KS. Distinctions
between endemic and HIV-related pediatric KS were also
observed, as we noted the uncommon occurrence of oral
lesions in HIV-negative patients, as well as a lower fre-
quency of visceral involvement in endemic KS.
These findings are consistent with previously pub-
lished reports on endemic KS in Africa (Table 3). The
predilection for lymph node involvement in both en-
demic and HIV-related KS emphasizes the importance
of recognizing KS as an important disease in the differ-
ential diagnosis for children with persistent lymphaden-
opathy in KSHV-endemic regions of Africa. Our
observation of infrequent oral involvement in endemic
KS has also been previously described and ranges from 0
to 10% in published historical cohorts from across the
region (Table 3). This contrasts with HIV-related
pediatric KS cohorts in the same region, in which oral
KS lesions have been reported in 21–58% of patients
[19]. It is more challenging to confirm the true incidence
of visceral disease in endemic KS because of limitations
in resources required to confidently establish the diagno-
sis in low-income countries. Additionally, there appeared
to be a male predominance in endemic KS, although
similar to the comparison of visceral involvement, this
failed to meet statistical significance. Historically, en-
demic KS cohorts ranged from 70 to 84% male in publi-
cations including at least 20 subjects, while male
representation in HIV-related pediatric KS has ranged
from 50 to 73% [19]. While these data, as well as the his-
torical precedents are limited by sample size, it is
Table 2 Characteristics of Children and Adolescents with Endemic KS in Context of a Pediatric-Specific Staging Classification
Stage 1: Mild/Moderate
Cutaneous/Oral KS
Stage 2: Lymphadenopathic KS Stage 3: Woody
Edema KS
Stage 4: Visceral and/or
Disseminated Cutaneous/
Oral KS
Number of patients, n 4 6 6 4
Baseline Anemia (hgb < 8), n (%) 0 5 (83%) 1 (17%) 3 (75%)
Baseline Thrombocytopenia
(platelet count < 100), n (%)
1 (25%) 4 (67%) 0 3 (75%)
Alive in complete remission, n (%) 3 (75%) 5 (83%) 1 (17%) 0
Alive with stable disease, n (%) 0 0 3 (50%) 1 (25%)
Deaths, n (%) 1 (25%) 1 (17%) 2 (33%) 3 (75%)
KS related death 0 1 2 3
Non-KS related death 1 0 0 0
2-year EFS in HIV+ KS cohorta too few patients to determine 73% 29% 0
2-year OS in HIV+ KS cohorta 75% 79% 12%
Legend: KS Kaposi sarcoma, hgb hemoglobin, EFS event-free survival, OS overall survival, areferences the published historical HIV-related pediatric KS cohort
(reference number 17)
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plausible that subtle distinctions between the two epi-
demiological variants of pediatric KS in Africa exist.
Reviewing HIV-related parameters of the HIV-infected
pediatric KS cohort, a few important observations are
noted that may explain the clinical overlap with endemic
disease. Severe CD4 count suppression was infrequent,
observed in only 28% of the HIV-related cohort [16].
Additionally, 49% of the HIV-related cohort was already
on antiretroviral therapy at the time of KS diagnosis, half
of them for more than 12 months [16]. Considering the
relatively high proportion of HIV-infected children de-
veloping KS despite having immunocompetent CD4
counts and/or on antiretroviral therapy, it appears that
the immunologic context in which HIV-related and
endemic KS occurs is often similar, and potentially more
attributed to an undefined qualitative immune dysfunc-
tion rather than a severe quantitative suppression of the
CD4 count. The authors hypothesize that this may pro-
vide rationale for the often-overlapping clinical features
observed, and may even become more apparent in the
future with increasing access to antiretroviral therapy.
The occurrence of moderate-severe anemia and
thrombocytopenia as a presenting clinical feature of
pediatric KS has been consistent in the experiences with
both HIV-negative and HIV-related disease in Malawi.
Although numbers are too small in this cohort to evaluate
clinical associations, presentation with cytopenias was
not found to have an impact on survival in HIV-related
pediatric KS [16]. Baseline cytopenias were significantly
more likely to occur in HIV-infected children with
stage 2 lymphadenopathic KS and stage 4 visceral and/
or disseminated cutaneous/oral KS, and this pattern ap-
pears to be consistent in our experience with endemic
KS as well (Table 2) [17].
Considering the frequent occurrence of cytopenias as
well as the overlapping clinical patterns of disease in both
epidemiological variants of pediatric KS, it is plausible that
KSHV-driven pathways may play an important biological
role in determining the clinical phenotype of disease.
Recent pilot data from HIV-infected children in Malawi
demonstrated associations between elevated plasma KSHV
viral load and lymphadenopathic KS, and although sample
size limited the statistical power of the results, it was not-
able that all 5 patients with anemia as well as all 4 patients
with thrombocytopenia demonstrated detectable KSHV
viral loads at the time of KS diagnosis [21]. If the clinical
features are driven by KSHV-mediated pathways, they may
be more attributed to mechanisms of KSHV pathogen-
esis, and therefore less dependent on the underlying
HIV-status. Additionally, elevated interleukin-6 (IL-6)
levels were common in the pilot pediatric cohort, and
the links between lytic activation of KSHV, elevated
viral load and IL-6 levels, and clinical presentation with
cytopenias have been well established in adults with
other KSHV-associated malignancies including multicentric
Castleman disease (MCD) and the KSHV inflammatory
cytokine syndrome (KICS) [21, 22]. Based on this, the au-
thors hypothesize that analogous to the KSHV-driven viral
pathophysiology in MCD and KICS, lytic activation of
KSHV in subsets of both HIV-positive and HIV-negative
pediatric KS patients may be linked with specific clin-
ical findings (eg KS lymphadenopathy, visceral/dis-
seminated disease, and the presence of anemia and
thrombocytopenia). Ultimately, biological assessments
of both epidemiological variants are required to establish
the precise pathophysiological mechanisms driving the
distinct clinical features that have been observed.
Cancer registry data and GLOBOCAN estimates
demonstrate that alongside lymphoma (including Burkitt,
Hodgkin, and non-Burkitt non-Hodgkin lymphoma),
Wilms tumor, retinoblastoma, and leukemia, KS has
become one of the top five most common overall child-
hood malignancies in several countries in eastern and
central Africa including Malawi, Uganda, Kenya, Tanzania,
Rwanda, Mozambique, Zambia, and Zimbabwe [23].
Contemporary pediatric KS publications from this region
though, have mostly focused on HIV-infected patients.
Although rates of HIV-related KS exceed those of en-
demic disease in this era of the HIV epidemic, it is import-
ant to establish a treatment paradigm that includes
children with endemic KS as well [9]. Observations from
this study suggest that overall outcomes between endemic
Table 3 Comparison of Clinical Features Among Endemic HIV-Negative Pediatric KS Cohorts in Africa
Location(s) Time
Period
n Age of Cohort % Male
Gender
Original Clinical Presentation with KS Involvement of:
Lymph Node Skin Lesions Woody Edema Oral Lesions Visceral Disease
Uganda/Tanzania 3 1957–65 51 median 10 years 76% 53% 53% no mention no mention no mention
Uganda 4 1968–75 12 median 8 years 58% 83% 17% no mention 8% 8%
Tanzania 6 1968–82 73 63% under 5 years 84% 48% uncertain no mention 1% no mention
Kenya 7 1997–99 8 median 7 years 88% 75% 38% uncertain 0 13%
Blantyre, Malawi 8 2002–14 20 median 4 years 80% 60% 40% 70% 10% uncertain
Lilongwe, Malawi 2011–16 20 median 9 years 70% 50% 45% 40% 5% 0
Legend: KS Kaposi sarcoma, no mention = indicates that these data were not mentioned at all in the publication, uncertain = indicates that although the topic was
mentioned in the publication, discrete numbers were not reported. Associated references are listed in superscript in the first column
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and HIV-related cohorts are similar in the context of read-
ily available antiretroviral therapy for HIV-infected pa-
tients. Although there are not enough patients in this
analysis to draw definitive conclusions, prognosis appears
to correlate more with the clinical phenotype of disease
presentation (ie their classification in a pediatric-specific
risk-stratification platform) rather than the underlying
epidemiological classification of the disease.
Ultimately, it appears that there is significant overlap in
the clinical features between endemic and HIV-related KS
in children and adolescents in a KSHV-endemic region of
Africa. The authors advocate for a universal risk-stratified
treatment approach that applies to both endemic and
HIV-related pediatric KS. Systematically characterizing
the treatment response for children with endemic disease
will be essential to improving overall outcomes.
Additional file
Additional file 1: Figure S1. Lymph Node Histopathology in Patients
with Endemic HIV-Negative and Epidemic HIV-Positive Lymphadeno-
pathic Kaposi Sarcoma. Lymph node biopsies from endemic HIV-negative
(A) and epidemic HIV-positive (B) children with lymphadenopathic Kaposi
sarcoma demonstrating diffuse spindle cell tumor infiltrates that stain
positive for the Kaposi sarcoma herpesvirus/human herpesvirus-8
latency-associated nuclear antigen immunohistochemical stain at
200x magnification. (TIF 7072 kb)
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